Back to top
more

Envista (NVST)

(Delayed Data from NYSE)

$21.10 USD

21.10
1,979,088

-0.03 (-0.14%)

Updated Sep 16, 2025 03:59 PM ET

After-Market: $21.50 +0.40 (1.90%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Envista (NVST) Gains From New Acquisitions Amid FX Woes

by Zacks Equity Research

Envista's (NVST) implant businesses in Europe perform well on the back of disciplined commercial execution.

Zacks Equity Research

Envista (NVST) Q1 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Weakness in China and Russia and lower demand for large capital equipment hurts Envista's (NVST) Q1 revenues.

Zacks Equity Research

Envista (NVST) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of -7.32% and 0.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Envista (NVST) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of 6.12% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Canopy Growth Corporation (CGC) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Envista (NVST) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Envista (NVST) Q3 Earnings Match Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of 0% and 0.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Envista (NVST) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Envista (NVST) Q2 Earnings Top Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of 4.35% and 1.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: NanoString Technologies (NSTG) Q2 Earnings Expected to Decline

by Zacks Equity Research

NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Envista (NVST) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Envista (NVST) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of 6.82% and 0.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bio-Rad Laboratories (BIO) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Bio-Rad (BIO) delivered earnings and revenue surprises of 76.43% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Envista (NVST) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Charles River (CRL) DSA Arm Sees Growth, Cell Supply Sluggish

by Zacks Equity Research

The acquisitions of Cognate BioServices and Vigene Biosciences contribute to the growth of Charles River's (CRL) Manufacturing Solutions arm.

Zacks Equity Research

Henry Schein (HSIC) Up 10.1% Since Posting Q4 Earnings Beat

by Zacks Equity Research

Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.

Zacks Equity Research

Syneos Health (SYNH) Q4 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Syneos Health (SYNH) reports better-than-expected earnings for the fourth quarter and strong performances by the Clinical Solutions and Commercial Solutions arms.

Zacks Equity Research

Globus Medical (GMED) Q4 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Strength in Musculoskeletal Solutions and Enabling Technologies products drove Globus Medical's (GMED) Q4 revenues.

Zacks Equity Research

Is Indivior PLC (INVVY) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Indivior PLC (INVVY) and Envista (NVST) have performed compared to their sector so far this year.

Zacks Equity Research

Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Grow

by Zacks Equity Research

Robust performances by all three operating businesses drove Henry Schein's (HSIC) Q4 revenues.

Zacks Equity Research

Omnicell (OMCL) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Robust performance by the Product and Service segments is driving Omnicell's (OMCL) fourth-quarter top line.

Zacks Equity Research

Envista (NVST) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of 9.52% and 2.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Envista (NVST) Could Beat Earnings Estimates Again

by Zacks Equity Research

Envista (NVST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Envista (NVST) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Envista (NVST) Gets FDA 510 (k) Approval for N1 Implant System

by Zacks Equity Research

Envista (NVST) noted that the Nobel Biocare N1 system represents a significant step further in patient-centric dental implant solutions.